Summary
BeiGene, Ltd. (ONC) filed an 8-K on December 14, 2021, detailing significant corporate and clinical updates. The company announced the commencement of its initial public offering on the Shanghai Stock Exchange's STAR Market, with shares expected to begin trading on December 15, 2021. This offering aims to raise capital by issuing ordinary shares in China. In addition to the STAR Offering, BeiGene highlighted substantial progress in its clinical pipeline. The company presented positive results from its RATIONALE 309 trial for tislelizumab in nasopharyngeal cancer and updated safety and efficacy data for BRUKINSA (zanubrutinib) in B-cell malignancies at major medical conferences. Furthermore, BeiGene announced a licensing and collaboration agreement with Nanjing Leads Biolabs, Inc. for LBL-007, a novel anti-LAG-3 antibody, securing worldwide rights outside of China. These developments underscore BeiGene's strategic focus on expanding its global presence and advancing its innovative drug candidates.
Key Highlights
- 1Commencement of BeiGene's initial public offering (STAR Offering) on the Shanghai Stock Exchange's STAR Market, with expected listing and trading on December 15, 2021.
- 2Presentation of positive results from the Phase 3 RATIONALE 309 trial of tislelizumab in first-line treatment for recurrent or metastatic nasopharyngeal cancer (RM-NPC).
- 3Disclosure of updated safety and efficacy data for BRUKINSA® (zanubrutinib) in patients with previously treated B-cell malignancies intolerant to other BTK inhibitors.
- 4Announcement of positive data from a planned interim analysis of the Phase 3 SEQUOIA trial for BRUKINSA in first-line chronic lymphocytic leukemia (CLL).
- 5Entry into a license and collaboration agreement with Nanjing Leads Biolabs, Inc. for LBL-007, a novel investigational antibody targeting the LAG-3 pathway, granting BeiGene worldwide rights outside of China.
- 6Issuance of multiple press releases attached as exhibits detailing these clinical trial results and corporate agreements.